Fig. 3 | Scientific Reports

Fig. 3

From: First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

Fig. 3

Rankograms of cumulative efficacy probabilities for (A) overall survival (OS), (B) progression-free survival (PFS), (C) intracranial progression-free survival (iPFS), (D) intracranial objective response rate (iORR), and (E) intracranial disease control rate (iDCR) in EGFR-mutant NSCLC with brain metastases, ordered from highest to lowest probability from top to bottom.

Back to article page